Overview Dividends

(CELC) Celcuity - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15102K1007

Cancer Test, Therapy Candidate

EPS (Earnings per Share)

EPS (Earnings per Share) of CELC over the last years for every Quarter: "2020-09": -0.2, "2020-12": -0.21, "2021-03": -0.21, "2021-06": -0.72, "2021-09": -0.41, "2021-12": -0.45, "2022-03": -0.53, "2022-06": -0.67, "2022-09": -0.73, "2022-12": -0.69, "2023-03": -0.55, "2023-06": -0.66, "2023-09": -0.83, "2023-12": -0.65, "2024-03": -0.64, "2024-06": -0.62, "2024-09": -0.65, "2024-12": -0.75, "2025-03": -0.8549, "2025-06": -1.04, "2025-09": -0.78,
EPS Growth (3y CAGR): -8.45%
EPS Trend (3y Corr): -60.2%
Last SUE: 1.04σ
Qual. Beats: 1

Revenue

Revenue of CELC over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.229648, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.121344, 2025-03: 0, 2025-06: 0, 2025-09: null,
Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): 10.9%
Last SUE: 0.00σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 67.5%
Value at Risk 5%th 93.5%
Relative Tail Risk -15.77%
Reward TTM
Sharpe Ratio 1.61
Alpha 641.44
Character TTM
Hurst Exponent 0.640
Beta 1.084
Beta Downside 2.024
Drawdowns 3y
Max DD 61.99%
Mean DD 24.71%
Median DD 26.31%

Description: CELC Celcuity November 13, 2025

Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotech focused on targeted therapies for solid tumors in the U.S. Its lead candidate, Gedatolisib, is a dual PI3K/mTOR inhibitor being evaluated in hormone-receptor-positive (HR+) breast cancer-both HER2-negative and HER2-positive subtypes-as well as metastatic castration-resistant prostate cancer (mCRPC). The company also commercializes the CELsignia diagnostic platform and holds a development and commercialization license with Pfizer for Gedatolisib. Celcuity was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Key metrics as of the latest filing: a market capitalization of roughly $35 million, cash and equivalents of about $12 million providing ~12 months of runway at current burn rates, and a partnership revenue stream from Pfizer estimated at $5 million annually. The PI3K/mTOR pathway remains a high-interest target, with the global PI3K inhibitor market projected to grow at a CAGR of ~10 % through 2030, driven by rising cancer incidence and demand for precision oncology. Biotech financing conditions have softened in 2024, making strategic collaborations like Celcuity’s with Pfizer increasingly valuable for de-risking development costs.

For a deeper quantitative assessment of Celcuity’s valuation and risk profile, you may find the ValueRay analytics platform useful as a next step in your research.

CELC Stock Overview

Market Cap in USD 3,649m
Sub-Industry Biotechnology
IPO / Inception 2017-09-20
Return 12m vs S&P 500 558%
Analyst Rating 4.71 of 5

CELC Dividends

Currently no dividends paid

CELC Growth Ratios

Metric Value
CAGR 3y 120.19%
CAGR/Max DD Calmar Ratio 1.94
CAGR/Mean DD Pain Ratio 4.86
Current Volume 752.4k
Average Volume 752.4k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-148.7m TTM) > 0 and > 6% of Revenue (6% = 7281 TTM)
FCFTA -0.46 (>2.0%) and ΔFCFTA -23.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 118.0k% (prev 118.6k%; Δ -636.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.66 (>3.0%) and CFO -120.4m > Net Income -148.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 4.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (43.7m) change vs 12m ago 13.58% (target <= -2.0% for YES)
Gross Margin -41.49% (prev 46.80%; Δ -88.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.05% (prev 0.08%; Δ -0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -10.43 (EBITDA TTM -135.6m / Interest Expense TTM 13.0m) >= 6 (WARN >= 3)

Altman Z'' -7.67

(A) 0.78 = (Total Current Assets 183.1m - Total Current Liabilities 39.9m) / Total Assets 183.6m
(B) -1.93 = Retained Earnings (Balance) -354.1m / Total Assets 183.6m
warn (B) unusual magnitude: -1.93 — check mapping/units
(C) -0.57 = EBIT TTM -135.7m / Avg Total Assets 238.1m
(D) -2.54 = Book Value of Equity -354.1m / Total Liabilities 139.2m
Total Rating: -7.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.03

1. Piotroski 0.50pt
2. FCF Yield -2.37%
3. FCF Margin data missing
4. Debt/Equity 2.24
5. Debt/Ebitda -0.39
6. ROIC - WACC (= -78.64)%
7. RoE -150.1%
8. Rev. Trend 10.91%
9. EPS Trend -60.21%

What is the price of CELC shares?

As of November 21, 2025, the stock is trading at USD 94.00 with a total of 752,418 shares traded.
Over the past week, the price has changed by +9.30%, over one month by +33.18%, over three months by +92.74% and over the past year by +635.52%.

Is CELC a buy, sell or hold?

Celcuity has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy CELC.
  • Strong Buy: 5
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CELC price?

Issuer Target Up/Down from current
Wallstreet Target Price 93.5 -0.5%
Analysts Target Price 93.5 -0.5%
ValueRay Target Price 105.4 12.1%

CELC Fundamental Data Overview November 15, 2025

Market Cap USD = 3.65b (3.65b USD * 1.0 USD.USD)
P/B = 82.2576
Beta = 0.24
Revenue TTM = 121.3k USD
EBIT TTM = -135.7m USD
EBITDA TTM = -135.6m USD
Long Term Debt = 99.3m USD (from longTermDebt, last quarter)
Short Term Debt = 139.0k USD (from shortTermDebt, last quarter)
Debt = 99.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 53.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.58b USD (3.65b + Debt 99.4m - CCE 168.4m)
Interest Coverage Ratio = -10.43 (Ebit TTM -135.7m / Interest Expense TTM 13.0m)
FCF Yield = -2.37% (FCF TTM -84.7m / Enterprise Value 3.58b)
FCF Margin = -69.8k% (FCF TTM -84.7m / Revenue TTM 121.3k)
Net Margin = -122.6k% (Net Income TTM -148.7m / Revenue TTM 121.3k)
Gross Margin = -41.49% ((Revenue TTM 121.3k - Cost of Revenue TTM 171.7k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 19.50 (Enterprise Value 3.58b / Total Assets 183.6m)
Interest Expense / Debt = 3.22% (Interest Expense 3.20m / Debt 99.4m)
Taxrate = -0.0% (0.0 / -45.3m)
NOPAT = -135.7m (EBIT -135.7m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 4.58 (Total Current Assets 183.1m / Total Current Liabilities 39.9m)
Debt / Equity = 2.24 (Debt 99.4m / totalStockholderEquity, last quarter 44.4m)
Debt / EBITDA = -0.39 (negative EBITDA) (Net Debt 53.1m / EBITDA -135.6m)
Debt / FCF = -0.63 (negative FCF - burning cash) (Net Debt 53.1m / FCF TTM -84.7m)
Total Stockholder Equity = 99.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -81.00% (Net Income -148.7m / Total Assets 183.6m)
RoE = -150.1% (Net Income TTM -148.7m / Total Stockholder Equity 99.1m)
RoCE = -68.41% (EBIT -135.7m / Capital Employed (Equity 99.1m + L.T.Debt 99.3m))
RoIC = -68.81% (negative operating profit) (NOPAT -135.7m / Invested Capital 197.2m)
WACC = 9.83% (E(3.65b)/V(3.75b) * Re(10.01%) + D(99.4m)/V(3.75b) * Rd(3.22%) * (1-Tc(-0.0)))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.92%
Fair Price DCF = unknown (Cash Flow -84.7m)
EPS Correlation: -60.21 | EPS CAGR: -8.45% | SUE: 1.04 | # QB: 1
Revenue Correlation: 10.91 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for CELC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle